• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

阿戈美拉汀通过协同发挥褪黑素能和 5-HT2C 受体依赖途径阻断应激诱导的大鼠前额叶/额叶皮质谷氨酸释放增加。

Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways.

机构信息

Center of Neuropharmacology - Department of Pharmacological Sciences and Center of Excellence on Neurodegenerative Diseases, University of Milano, Italy.

出版信息

BMC Neurosci. 2010 Jun 3;11:68. doi: 10.1186/1471-2202-11-68.

DOI:10.1186/1471-2202-11-68
PMID:20525261
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2896952/
Abstract

BACKGROUND

Agomelatine is a melatonergic receptor agonist and a 5HT2C receptor antagonist that has shown antidepressant efficacy. In order to analyze separately the effect of the two receptorial components, rats were chronically treated with agomelatine, melatonin (endogenous melatonergic agonist), or S32006 (5-HT2C antagonist), and then subjected to acute footshock-stress.

RESULTS

Only chronic agomelatine, but not melatonin or S32006, completely prevented the stress-induced increase of glutamate release in the rat prefrontal/frontal cortex.

CONCLUSIONS

These results suggest a potential synergy between melatonergic and serotonergic pathways in the action of agomelatine.

摘要

背景

阿戈美拉汀是一种褪黑素受体激动剂和 5HT2C 受体拮抗剂，具有抗抑郁作用。为了分别分析这两种受体成分的作用，大鼠接受了阿戈美拉汀、褪黑素（内源性褪黑素激动剂）或 S32006（5-HT2C 拮抗剂）的慢性治疗，然后进行急性足底电击应激。

结果

只有慢性阿戈美拉汀，而不是褪黑素或 S32006，完全阻止了应激引起的大鼠前额叶/额叶皮质谷氨酸释放的增加。

结论

这些结果表明，阿戈美拉汀的作用中存在褪黑素和 5-羟色胺能途径之间的潜在协同作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e20/2896952/d092f54cb7e9/1471-2202-11-68-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e20/2896952/d092f54cb7e9/1471-2202-11-68-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e20/2896952/d092f54cb7e9/1471-2202-11-68-1.jpg

相似文献

1
Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways.阿戈美拉汀通过协同发挥褪黑素能和 5-HT2C 受体依赖途径阻断应激诱导的大鼠前额叶/额叶皮质谷氨酸释放增加。
BMC Neurosci. 2010 Jun 3;11:68. doi: 10.1186/1471-2202-11-68.
2
Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and to the 5-HT(2c) antagonist, S32006.阿戈美拉汀抑制嗅球切除术大鼠的运动过度活跃：与褪黑素和 5-HT2c 拮抗剂 S32006 的比较。
Eur J Pharmacol. 2012 Jan 5;674(1):27-32. doi: 10.1016/j.ejphar.2011.10.010. Epub 2011 Oct 21.
3
The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors.褪黑素激动剂和临床有效的抗抑郁药阿戈美拉汀是 5-HT（2C）受体的中性拮抗剂。
Int J Neuropsychopharmacol. 2011 Jul;14(6):768-83. doi: 10.1017/S1461145710001045. Epub 2010 Oct 15.
4
Agomelatine affects rat suprachiasmatic nucleus neurons via melatonin and serotonin receptors.阿戈美拉汀通过褪黑素和5-羟色胺受体影响大鼠视交叉上核神经元。
Life Sci. 2016 Jun 15;155:147-54. doi: 10.1016/j.lfs.2016.04.035. Epub 2016 May 24.
5
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.新型褪黑素激动剂阿戈美拉汀（S20098）是5-羟色胺2C受体拮抗剂，阻断该受体可增强额叶皮质多巴胺能和肾上腺素能通路的活性。
J Pharmacol Exp Ther. 2003 Sep;306(3):954-64. doi: 10.1124/jpet.103.051797. Epub 2003 May 15.
6
Agomelatine in the tree shrew model of depression: effects on stress-induced nocturnal hyperthermia and hormonal status.阿戈美拉汀在树鼩抑郁模型中的作用：对压力诱导的夜间体温过高及激素状态的影响。
Eur Neuropsychopharmacol. 2014 Mar;24(3):437-47. doi: 10.1016/j.euroneuro.2013.07.010. Epub 2013 Aug 2.
7
Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration.急性给予阿戈美拉汀后调节大鼠前额皮质神经营养因子 BDNF 的协同机制。
World J Biol Psychiatry. 2010 Mar;11(2):148-53. doi: 10.3109/15622970903447659.
8
Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.新型抗抑郁药及褪黑素激动剂/5-羟色胺2C受体拮抗剂阿戈美拉汀对大鼠睡眠-觉醒周期结构的影响。
Psychopharmacology (Berl). 2009 Jul;205(1):93-106. doi: 10.1007/s00213-009-1519-2. Epub 2009 Apr 16.
9
Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors.阿戈美拉汀的作用模式：褪黑素能和 5-HT2C 受体的协同作用。
World J Biol Psychiatry. 2011 Dec;12(8):574-87. doi: 10.3109/15622975.2011.595823. Epub 2011 Oct 14.
10
Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats.阿戈美拉汀（S 20098）可拮抗Wistar大鼠中5-HT2C受体刺激所诱导的阴茎勃起。
Psychopharmacology (Berl). 2003 Oct;170(1):17-22. doi: 10.1007/s00213-003-1465-3. Epub 2003 Aug 7.

引用本文的文献

1
Stress-related cellular pathophysiology as a crosstalk risk factor for neurocognitive and psychiatric disorders.应激相关的细胞病理生理学作为神经认知和精神障碍的串扰风险因素。
BMC Neurosci. 2023 Dec 12;24(1):65. doi: 10.1186/s12868-023-00831-2.
2
Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial.阿戈美拉汀增强舍曲林治疗中重度强迫症：一项随机、双盲、安慰剂对照的临床试验。
BMC Psychiatry. 2023 Sep 21;23(1):686. doi: 10.1186/s12888-023-05189-7.
3
Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease.

本文引用的文献

1
Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration.急性给予阿戈美拉汀后调节大鼠前额皮质神经营养因子 BDNF 的协同机制。
World J Biol Psychiatry. 2010 Mar;11(2):148-53. doi: 10.3109/15622970903447659.
2
Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants.急性应激增加大鼠前额叶/额叶皮层去极化诱发的谷氨酸释放：抗抑郁药的抑制作用。
PLoS One. 2010 Jan 5;5(1):e8566. doi: 10.1371/journal.pone.0008566.
3
Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
阿戈美拉汀：一种治疗神经退行性疾病记忆障碍的潜在新方法。
Neural Regen Res. 2023 Apr;18(4):727-733. doi: 10.4103/1673-5374.353479.
4
Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.阿戈美拉汀治疗广泛性焦虑障碍：聚焦其独特作用机制
Ther Adv Psychopharmacol. 2022 Jun 30;12:20451253221105128. doi: 10.1177/20451253221105128. eCollection 2022.
5
Acute Ketamine Facilitates Fear Memory Extinction in a Rat Model of PTSD Along With Restoring Glutamatergic Alterations and Dendritic Atrophy in the Prefrontal Cortex.急性氯胺酮可促进创伤后应激障碍大鼠模型中的恐惧记忆消退，并恢复前额叶皮层的谷氨酸能改变和树突萎缩。
Front Pharmacol. 2022 Mar 17;13:759626. doi: 10.3389/fphar.2022.759626. eCollection 2022.
6
Chronobiology Revisited in Psychiatric Disorders: From a Translational Perspective.从转化医学角度重新审视精神疾病中的时间生物学
Psychiatry Investig. 2020 Aug;17(8):725-743. doi: 10.30773/pi.2020.0129. Epub 2020 Aug 6.
7
The effects of agomelatine and imipramine on liver cytochrome P450 during chronic mild stress (CMS) in the rat.阿戈美拉汀和丙咪嗪对大鼠慢性轻度应激（CMS）期间肝脏细胞色素P450的影响。
Pharmacol Rep. 2020 Oct;72(5):1271-1287. doi: 10.1007/s43440-020-00151-w. Epub 2020 Aug 3.
8
Anxiolytic properties of compounds that counteract oxidative stress, neuroinflammation, and glutamatergic dysfunction: a review.对抗氧化应激、神经炎症和谷氨酸能功能障碍的化合物的抗焦虑特性：综述。
Braz J Psychiatry. 2019 Mar-Apr;41(2):168-178. doi: 10.1590/1516-4446-2018-0005. Epub 2018 Oct 11.
9
Molecular and Epigenetic Mechanisms for the Complex Effects of Stress on Synaptic Physiology and Cognitive Functions.应激对突触生理学和认知功能的复杂影响的分子和表观遗传机制。
Int J Neuropsychopharmacol. 2017 Nov 1;20(11):948-955. doi: 10.1093/ijnp/pyx052.
10
Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks.阿戈美拉汀治疗重性抑郁障碍：获益与风险评估。
Curr Neuropharmacol. 2014 Sep;12(5):287-398. doi: 10.2174/1570159X12999140619122914.
阿戈美拉汀可预防无停药综合征证据的重度抑郁症患者复发：一项为期24周的随机、双盲、安慰剂对照试验。
J Clin Psychiatry. 2009 Aug;70(8):1128-37. doi: 10.4088/JCP.08m04548. Epub 2009 Aug 11.
4
Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus.新型抗抑郁药阿戈美拉汀对成年大鼠海马神经发生进行阶段依赖性调节的作用机制。
Neuropsychopharmacology. 2009 Oct;34(11):2390-403. doi: 10.1038/npp.2009.72. Epub 2009 Jul 1.
5
S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.S32006，一种新型5-羟色胺2C受体拮抗剂，在啮齿动物模型中显示出广泛的抗抑郁和抗焦虑特性。
Psychopharmacology (Berl). 2008 Sep;199(4):549-68. doi: 10.1007/s00213-008-1177-9. Epub 2008 Jun 4.
6
Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex.反复给予丙咪嗪可减弱大鼠额叶皮质中的谷氨酸能传递。
Neuroscience. 2008 May 15;153(3):789-95. doi: 10.1016/j.neuroscience.2008.03.007. Epub 2008 Mar 8.
7
Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine).重度抑郁症患者的非快速眼动睡眠不稳定性：主观改善及治疗（阿戈美拉汀）对非快速眼动睡眠不稳定性的改善
Sleep Med. 2007 Dec;9(1):33-41. doi: 10.1016/j.sleep.2007.01.011. Epub 2007 Sep 7.
8
Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus.抗抑郁药治疗与海马体中介导胺释放的离子型谷氨酸受体的功能
Neuropharmacology. 2007 Jul;53(1):27-36. doi: 10.1016/j.neuropharm.2007.04.006. Epub 2007 Apr 29.
9
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.阿戈美拉汀（一种具有5-HT2C拮抗特性的MT1/MT2受体激动剂）治疗重度抑郁症的疗效
Int J Neuropsychopharmacol. 2007 Oct;10(5):661-73. doi: 10.1017/S1461145707007766. Epub 2007 May 4.
10
Chronic antidepressants induce redistribution and differential activation of alphaCaM kinase II between presynaptic compartments.慢性抗抑郁药会导致α钙调蛋白激酶II在突触前区室之间重新分布并产生不同程度的激活。
Neuropsychopharmacology. 2007 Dec;32(12):2511-9. doi: 10.1038/sj.npp.1301378. Epub 2007 Mar 14.